Oncoinvent
Tracked across 2 events · 13 articles · First seen Jun 18, 2026 · Last active Aug 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Oncoinvent announced reaching the 50% patient recruitment milestone in its Phase 2 trial for Radspherin, indicating progress in its clinical development and potential for future commercial success.
Jun 18, 2026 · 7 articles
Tech
Impact: Oncoinvent is the developer of Radspherin and the primary subject of the announcement. The publication of favorable dosimetry data supports its clinical program and could enhance its commercial prospects.
Aug 11, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Oncoinvent live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard